US2020060991A1PendingUtilityA1

Methods for the treatment of erectile dysfunction using fispemifene

53
Assignee: QUATRX PHARMACEUTICALSPriority: Jun 13, 2007Filed: Nov 1, 2019Published: Feb 27, 2020
Est. expiryJun 13, 2027(~0.9 yrs left)· nominal 20-yr term from priority
A61P 15/10A61P 15/00A61K 31/4985A61K 31/135A61K 9/00A61K 31/519A61K 31/53A61K 31/085A61K 31/075A61K 31/496
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.

Claims

exact text as granted — not AI-modified
1 . A method of raising testosterone, luteinizing hormone, and follicle-stimulating hormone in a subject suffering from erectile dysfunction and secondary hypogonadism comprising administering an amount of fispemifene sufficient to raise levels of testosterone, luteinizing hormone, and follicle-stimulating hormone. 
     
     
         2 . The method of  claim 1  wherein the amount of fispemifene is effective to treat the erectile dysfunction. 
     
     
         3 . The method of  claim 1  further comprising administering a therapeutically effective amount of a PDE-5 inhibitor to treat the erectile dysfunction.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.